| pubmed-article:17495423 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0028833 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0205322 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0439231 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0732165 | lld:lifeskim |
| pubmed-article:17495423 | lifeskim:mentions | umls-concept:C0682002 | lld:lifeskim |
| pubmed-article:17495423 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17495423 | pubmed:dateCreated | 2007-7-20 | lld:pubmed |
| pubmed-article:17495423 | pubmed:abstractText | The objective of the present study was to investigate the effects of octreotide long acting release (S-LAR) preparation on GH and IGF-1 serum concentrations and pituitary tumor size in patients with persistent and difficultly controlled acromegaly even after adjuvant irradiation and/or dopamine agonists. Thirty-three patients with active acromegaly (26 female and 7 male, mean age; 43.94 +/- 14.01 SD years) were included in this study. Patients were evaluated at baseline and at 6, 12, 30 and 40 months for GH, IGF-1, and GH response to OGTT and biliary ultrasonography. Sella MRI was performed at initial and at 40 months. All patients received 20 mg S-LAR. Afterwards, the dosage was titrated to improve individual GH response and reduction of IGF-1 into normal ranges. Basal serum IGF-1 levels decreased from median: 530 microg/l [IQR: 420-600] to 340 microg/l [IQR: 230-460] at 6 months (p = 0.01), to 400 microg/l [IQR: 222.4-600] at 12 months (p = 0.48), to 396 microg/l [IQR: 318-468] at 30 months (p = 0.49), to 482 microg/l [308-580] at 40 months (p = 0.47). Nadir GH levels in OGTT fell from 2.70 ng/ml [IQR: 1.35-6.90] to 1.60 ng/ml [IQR: 0.36-4.10] at 6 months (p = 0.03), to 0.31 ng/ml [IQR: 0.18-0.65] at 12 months (p<0.0001), to 1.50 ng/ml [IQR: 0.83-4.00] at 30 months (p = 0.398) and to 0.89 ng/ml [IQR: 0.58-1.35] at 40 months (p<0.0001). Initially, pituitary adenoma volume was median: 1.18 ml [IQR: 0.08-3.50] and it shrank to 0.21 ml [IQR: 0-2.1] at 40 months (p = 0.08). Gallstones were detected in 12 patients and six of them underwent cholecystectomy. S-LAR is an effective treatment regimen in reducing GH and IGF-1 concentrations and as well as in shrinking tumor volume in persistent and difficultly controlled acromegalic patients. | lld:pubmed |
| pubmed-article:17495423 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17495423 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17495423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17495423 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17495423 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17495423 | pubmed:issn | 0918-8959 | lld:pubmed |
| pubmed-article:17495423 | pubmed:author | pubmed-author:TiryakiogluOz... | lld:pubmed |
| pubmed-article:17495423 | pubmed:author | pubmed-author:KadiogluPinar... | lld:pubmed |
| pubmed-article:17495423 | pubmed:author | pubmed-author:YalinAyse... | lld:pubmed |
| pubmed-article:17495423 | pubmed:author | pubmed-author:YetkinDemet... | lld:pubmed |
| pubmed-article:17495423 | pubmed:author | pubmed-author:BoysanSerife... | lld:pubmed |
| pubmed-article:17495423 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17495423 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:17495423 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17495423 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17495423 | pubmed:pagination | 459-64 | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:meshHeading | pubmed-meshheading:17495423... | lld:pubmed |
| pubmed-article:17495423 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17495423 | pubmed:articleTitle | Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. | lld:pubmed |
| pubmed-article:17495423 | pubmed:affiliation | Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey. | lld:pubmed |
| pubmed-article:17495423 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17495423 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17495423 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17495423 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17495423 | lld:pubmed |
